Biologics

Biopharmaceutical company Scholar Rock’s Isembyld treatment was approved by the FDA to treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2-targeted treatment. Isembyld is the…

Regentis Biomaterials has treated 43 of 80 patients in its pivotal U.S. trial evaluating GelrinC, a hydrogel implant for focal articular knee cartilage injuries. The company now expects to complete full enrollment on or around the end of 2026, compared…

Bone Biologics has doubled the number of Australian hospital sites participating in its first-in-human pilot clinical trial of NB1, its bone graft product for spinal fusion. Six hospital sites are now under agreement to participate in the trial. The company…

Researchers at New York City-based Weill Cornell Medicine and Hospital for Special Surgery identified stem cells that give rise to tendons and ligaments and found that their overactivity may contribute to lumbar spinal stenosis. The researchers identified the stem cells…

Tampa, Fla.-based Joseph Spine Institute launched a Regenerative Therapy Center offering autologous adipose-derived cell therapies and platelet-rich plasma for spine and musculoskeletal care. The practice said the center will combine regenerative therapies with spine diagnosis, interventional pain management, sports medicine…

University of California Los Angeles researchers found little evidence supporting the use of six emerging peptides for musculoskeletal treatment, tissue recovery or performance. The researchers reviewed 565 studies examining BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu. More than two-thirds of…

One of the most common criticisms I hear about peptides in orthopedics is straightforward: there isn’t enough human data. I agree. For compounds commonly discussed in orthopedics such as BPC-157, the preclinical literature is interesting, but the human musculoskeletal evidence…

Vector Science and Therapeutics, a medical technology and therapeutic delivery company, filed a provisional patent application covering a platform designed to improve tissue healing in orthopedic surgical care. The platform pairs tissue-repair-promoting peptides with a patient’s own platelet-rich plasma or…

Stefano Sinicropi, MD, an orthopedic spine surgeon, was appointed to Genesis Regenerative’s clinical advisory board. Dr. Sinicropi is president and CEO of Edina, Minn.-based Midwest Spine & Brain Institute and founder of HyperCharge Health, an integrative clinic offering nonsurgical care,…

GelrinC, Regentis Biomaterials’ cartilage-repair technology, received a Japanese Notice of Allowance for patent protection covering its organic solvent-free manufacturing process and ready-to-use liquid formulation. The Japanese patent allowance followed a recent U.S. patent issuance and expanded the company’s global intellectual…